{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2023
Source:
M006
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M020
(2023)
Source URL:
First approved in 2023
Source:
M020
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M005
(2023)
Source URL:
First approved in 2023
Source:
M005
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M017
(2023)
Source URL:
First approved in 2023
Source:
M017
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Sonifilan by Kaken Pharmaceutical
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
POLYMER
Targets:
Conditions:
Sizofiran (Schizophyllan, SPG, Sonifilan, Sizofilan) is a soluble beta-D-glucan produced by the Basidiomycetes fungus, Schizophyllum commune Fries, with potential immunomodulating and antitumor activities. Although sizofiran’s exact mechanism of action has yet to be fully elucidated, this agent appears to stimulate the immune system by increasing cytokine production, activating macrophages and Langerhans cells and enhancing the activity of polymorphonuclear leukocytes (PML) and natural killer (NK) cells. Sizofiran was found rather ineffective against gastric cancer, but extended survival time in patients with head and neck cancer. In cervical cancer, Sizofiran prolonged survival and time to recurrence for stage II cases but not stage III, and showed added effectiveness when injected directly into the tumor mass. Sonifilan is used as a biological response modifier (BRM) with radiation therapy for cancer treatment in Japan. It was launched for cervical cancer in South Korea in 1998.
Status:
Possibly Marketed Outside US
Source:
M016
(2023)
Source URL:
First approved in 2023
Source:
M016
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 2023
Source:
Herpes Relief Cream by Ehy Holdings LLC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M032
(2022)
Source URL:
First approved in 2022
Source:
M032
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2022)
Source URL:
First approved in 2022
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
POLYMER
